Sort

Search

01/01/2023 All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
Ling S., Zaccardi F., Vlacho B., Li P., Gatius, JR, Mata-Cases M., Franch-Nadal J., Kosiborod M.N., Gillies C., Fenici P., Mauricio D., Shah B.R., Khunti K.. All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. DIABETES OBESITY & METABOLISM. 2023; 25(1)DOI:10.1111/dom.14856. PMID:36056765. IF:5.400(Q1/2D).
01/01/2023 Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins
Reis A., Rocha S., Dias I.H., Costa R., Soares R., Sánchez-Quesada J.L., Perez A., de Freitas V.. Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins. Redox Biology. 2023; 59DOI:10.1016/j.redox.2022.102572. PMID:36516720. IF:10.700(Q1/1D).
01/01/2023 Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Muller-Wieland, D, Freemantle, N, Bonadonna, RC, Mauquoi, C, Bigot, G, Bonnemaire, M, Gourdy, P, Mauricio, D. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database. Diabetes Therapy. 2023; 14(2)DOI:10.1007/s13300-022-01356-3. PMID:36596946. IF:2.800(Q3/6D).
01/01/2023 Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project
Sánchez E., Sánchez M., López-Cano C., Bermúdez-López M., Valdivielso J.M., Farras-Salles, C, Pamplona R., Torres G., Mauricio D., Castro E., Fernández E., Lecube A.. Is There a Link between Obesity Indices and Skin Autofluorescence? A Response from the ILERVAS Project. Nutrients. 2023; 15(1)DOI:10.3390/nu15010203. PMID:36615860. IF:4.800(Q1/2D).
01/01/2023 Obesity and fertility. Position statement
Miñambres I., de Hollanda A., Vilarrasa N., Pellitero S., Rubio M.A., Flores L., Caixàs A., Lobo S., Martinez Salamanca J.I., Acevedo B., Moizé V., Andreu A., Escalada J.. Obesity and fertility. Position statement. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.10.002. PMID:. IF:(Q/D).
01/01/2023 Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología
Pedro-Botet J., Barrios V., Sánchez-Margalet V., Tamargo J., Arrieta F., Gámez J.M., Gimeno-Orna J.A., Escobar C., Gómez-Doblas J.J., Pérez A.. Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología. Endocrinologia Diabetes y Nutricion. 2023; 70DOI:10.1016/j.endinu.2022.03.004. PMID:. IF:(Q/D).